title: When assay format matters: a case study on the evaluation of three assay formats to support a clinical pharmacokinetic study.
abstract: Data generated using various immunoassay methods are an integral part of the development of protein therapeutics. These assays are used in clinical and preclinical studies to establish the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics as well as to assess the immunogenicity properties of a therapeutic. PK assays measure therapeutic levels post-administration which is essential for understanding the effective dose and dose regimen for a therapeutic. Anti-OX40L is a fully humanized monoclonal antibody designed for the potential treatment of an autoimmune disease. The anti-OX40L human PK assay is required to be sensitive, robust, and precise. To address challenges due to assay sensitivity and reproducibility, as well as assay technology limitations, during development of the anti-OX40L human PK assay, three different assays, including an MSD-based electrochemiluminescence assay (ECLA), a fluorometric enzyme-linked immunosorbent assay (ELISA), and a colorimetric ELISA, were evaluated. The MSD-based assay was the most sensitive but posed risk of inter-well signal crosstalk. The fluorescence ELISA fell short on reproducibility. The colorimetric ELISA was ultimately chosen for supporting sample analysis. This paper presents characterization data obtained from each of these assay formats, challenges that were encountered in the development of the assay, and the rationale for selecting the ultimate assay format.
authors.affiliation: Department of BioAnalytical Sciences, Genentech, 1 DNA Way, South San Francisco, California, 94080-4990, USA, peng.kun@gene.com.
authors.forename: Kun
authors.initials: K
authors.lastname: Peng
authors.forename: Dana
authors.initials: D
authors.lastname: Baker
authors.forename: Suzanne
authors.initials: S
authors.lastname: Brignoli
authors.forename: Janis
authors.initials: J
authors.lastname: Cabuhat
authors.forename: Saloumeh K
authors.initials: SK
authors.lastname: Fischer
mesh_terms: D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003124:Colorimetry; D004797:Enzyme-Linked Immunosorbent Assay; D005453:Fluorescence; D006801:Humans; D049449:Luminescence; D053278:OX40 Ligand / Q000032:analysis / Q000493:pharmacokinetics; D010599:Pharmacokinetics; D015203:Reproducibility of Results
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D053278:OX40 Ligand; C089251:TNFSF4 protein, human
references.citation: Pharm Res. 2003 Nov;20(11):1885-900
references.pmid: 14661937
references.citation: Talanta. 2001 May 30;54(4):531-59
references.pmid: 18968276
references.citation: J Pharm Biomed Anal. 2005 Jul 15;38(4):703-8
references.pmid: 15967298
references.citation: Curr Pharm Biotechnol. 2008 Dec;9(6):423-30
references.pmid: 19075682
references.citation: Immunochemistry. 1971 Sep;8(9):871-4
references.pmid: 5135623
references.citation: Bioanalysis. 2010 Jun;2(6):1125-40
references.pmid: 21083212
references.citation: Bioanalysis. 2009 Aug;1(5):919-35
references.pmid: 21083063
references.citation: Annu Rev Anal Chem (Palo Alto Calif). 2009;2:359-85
references.pmid: 20636067
references.citation: Chem Soc Rev. 2010 Aug;39(8):3275-304
references.pmid: 20593100
references.citation: Bioanalysis. 2011 Mar;3(6):597-603
references.pmid: 21417729
references.citation: AAPS J. 2011 Mar;13(1):99-110
references.pmid: 21240643